Orgenesis ( (ORGS) ) has released a notification of late filing.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Orgenesis Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The delay is primarily due to the company’s focus on capital raising and the need to first complete its Form 10-K (Yearly Report) for the year ended December 31, 2024. Orgenesis has indicated that it will not meet the five-day extension period for filing. The company expects to report a decrease in net loss for the period ended March 31, 2025, compared to the same period in 2024, due to reduced activities from funding constraints. Orgenesis is committed to completing its financial reporting requirements and improving its internal controls. The notification was signed by Victor Miller, the Chief Financial Officer.
Spark’s Take on ORGS Stock
According to Spark, TipRanks’ AI Analyst, ORGS is a Underperform.
Orgenesis faces substantial financial challenges, with negative revenue and cash flow issues indicating significant instability. Despite negative technical indicators, recent corporate governance improvements may provide a slight strategic advantage. However, these factors are overshadowed by the company’s overarching financial distress, resulting in a low overall stock score.
To see Spark’s full report on ORGS stock, click here.
More about Orgenesis
Average Trading Volume: 10,797
Technical Sentiment Signal: Sell
Current Market Cap: $9.77M
Find detailed analytics on ORGS stock on TipRanks’ Stock Analysis page.